For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Selling, general and administrative expenses | 2,887,358 | |||
| Research and development expenses | 121,085 | |||
| Stock-based compensation | 4,142,816 | |||
| Total operating expenses | 7,151,259 | |||
| Loss from operations | -7,151,259 | |||
| Interest income | 167,103 | |||
| Interest expense | 415,890 | |||
| Operating sublease income | 134,196 | |||
| Loss on foreign exchange changes | -77,546 | |||
| Loss on investment in equity securities | -192,759 | |||
| Loss on impairment of equity investment | -803,008 | |||
| Other (loss) income, net | -13,642 | |||
| Total other (expenses) | -1,201,546 | |||
| Loss before provision for income tax | -8,352,805 | |||
| Provision for income tax expense (benefit) | 24,154 | |||
| Net loss | -8,376,959 | |||
| Net loss attributable to noncontrolling interests | -468,405 | |||
| Net loss attributed to abvc and subsidiaries | -7,908,554 | |||
| Foreign currency translation adjustment | 41,937 | |||
| Comprehensive loss | -7,866,617 | |||
| Basic EPS | -0.39 | |||
| Diluted EPS | -0.39 | |||
| Basic Average Shares | 20,108,944 | |||
| Diluted Average Shares | 20,108,944 | |||
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)